See other companies on Welcome to the Jungle
Paige
AI digital diagnostics for cancer treatment
- 101-200 employees
- Healthcare
- B2B
- Artificial Intelligence
- Biology
- SaaS
- Theater District, New York, NY
Jump to section
Company mission
To use the incredible power of tissue-based AI to develop and deliver globally, a new generation of digital diagnostics and predictive tests, empowering pathologists and transforming oncology.
-22% employee growth in 12 months
Our take
Paige leverages AI and machine learning to better map the pathology of cancer. The company builds computational pathology products designed to allow patients and their healthcare teams to make more informed treatment decisions.
The company was founded by an impressive set of medical professionals – including Dr Thomas Fuchs, who is known for his work on computational pathology. It continues to grow thanks to a collective of specialists in pathology, machine learning, healthcare, and business.
Paige closed out its Series B funding at $70 million, which takes total fundraising to $195 million. This new investment puts them in a prime position to expand into the global digital pathology market, which is expected to reach revenues of $1.27 billion by 2026. The company is now investing in sales and marketing efforts, as well as doubling the number of employees.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Commuter spending account
- Paid parental leave
- A generous vacation policy
- Medical, dental, and vision insurance
- Work from home opportunities
- Health insurance
Company values
- Accountable - Be accountable to yourself and to others. Own your role
- Disruptive - Don’t settle for mediocrity. Trailblazing in a fast moving market is our business
- Execution-focused - Strategy without execution is just a pipedream. Make it happen
- Patient-centric - Keep the patient and our customer at the heart of everything we do, always
- Trusting - Build trust, be sincere, communicate clearly and team up to win!
Funding (last 2 of 7 rounds)
Mar 2023
$19.5m
SERIES C
Mar 2021
$25m
SERIES C
Total funding: $239.5m
This company has top investors
Leadership
Thomas Fuchs
(Chief Scientist)PhD in Machine Learning from ETH Zurich. Background as a professor at various medical schools. Currently also Dean of Artificial Intelligence and Human Health at Icahn School of Medicine, Mount Sinai.